Form 4: Director Murat Kalayoglu Reports Cartesian Therapeutics Stock Transactions

Director Murat Kalayoglu reported a conversion of preferred stock to common stock and a disposition of common stock in Cartesian Therapeutics, Inc. on April 2, 2026.

Summary

• Director Murat Kalayoglu, through a trust for his spouse and children, converted 22,740.03 shares of Series A Non-Voting Convertible Preferred Stock into 758,001 shares of common stock on April 2, 2026.
• The trust also disposed of 506,999 shares of common stock on April 2, 2026.
• Following these transactions, the trust beneficially owns 5,313,261 shares of common stock, held indirectly.
• The preferred stock conversion and subsequent common stock disposition are related to merger consideration and private placement purchases from November 2023.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports standard insider transactions (conversion and disposition) without providing new strategic information or significant financial performance indicators.

Positives

• Conversion of preferred stock to common stock can indicate a belief in the company's future value.
• The trust holds a significant number of common shares (5,313,261) following the transactions.

Negatives

• A disposition of 506,999 common shares was reported.

Risks

• The remaining Series A Non-Voting Convertible Preferred Stock held by the Trust is subject to a beneficial ownership limitation, the details of which are not specified.
• The filing mentions securities purchased in a private placement in November 2023, which may have specific terms or restrictions.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• The filing details transactions made by a trust for the benefit of the reporting person's spouse and children.
• The reporting person's spouse is a trustee of the Trust.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not inherently provide strategic updates. The nature of the transaction (conversion of preferred to common stock and disposition) is common following mergers or private placements.

Related Party Transactions

• The transactions involve a trust for the benefit of the reporting person's spouse and children, with the reporting person's spouse acting as a trustee.

Stakeholder Impact

• Shareholders may note the disposition of common stock by an insider, though the context of conversion from preferred stock and prior merger consideration should be considered.
• The beneficial ownership limitation on remaining preferred stock could impact future share counts for the trust.

Next Steps

• The trust's remaining Series A Non-Voting Convertible Preferred Stock is subject to a beneficial ownership limitation.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transaction, Cartesian Therapeutics, RNAC, Director, Convertible Preferred Stock, Common Stock, Trust, Merger Consideration